Jin Yang Pharmaceutical Co. Ltd (007370) - Net Assets
Based on the latest financial reports, Jin Yang Pharmaceutical Co. Ltd (007370) has net assets worth ₩159.98 Billion KRW (≈ $108.42 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩271.49 Billion ≈ $183.99 Million USD) and total liabilities (₩111.51 Billion ≈ $75.57 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Jin Yang Pharmaceutical Co. Ltd tangible net worth ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩159.98 Billion |
| % of Total Assets | 58.93% |
| Annual Growth Rate | 9.08% |
| 5-Year Change | 144.74% |
| 10-Year Change | 225.27% |
| Growth Volatility | 18.65 |
Jin Yang Pharmaceutical Co. Ltd - Net Assets Trend (2014–2025)
This chart illustrates how Jin Yang Pharmaceutical Co. Ltd's net assets have evolved over time, based on quarterly financial data. See Jin Yang Pharmaceutical Co. Ltd defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Jin Yang Pharmaceutical Co. Ltd (2014–2025)
The table below shows the annual net assets of Jin Yang Pharmaceutical Co. Ltd from 2014 to 2025. For live valuation and market cap data, see market cap of Jin Yang Pharmaceutical Co. Ltd.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | ₩159.86 Billion ≈ $108.33 Million |
+33.35% |
| 2024-12-31 | ₩119.88 Billion ≈ $81.24 Million |
+33.82% |
| 2023-12-31 | ₩89.58 Billion ≈ $60.71 Million |
+15.48% |
| 2022-12-31 | ₩77.58 Billion ≈ $52.57 Million |
+18.77% |
| 2021-12-31 | ₩65.32 Billion ≈ $44.26 Million |
+41.04% |
| 2020-12-31 | ₩46.31 Billion ≈ $31.38 Million |
+6.06% |
| 2019-12-31 | ₩43.67 Billion ≈ $29.59 Million |
+3.85% |
| 2018-12-31 | ₩42.05 Billion ≈ $28.50 Million |
-0.79% |
| 2017-12-31 | ₩42.38 Billion ≈ $28.72 Million |
-13.77% |
| 2016-12-31 | ₩49.15 Billion ≈ $33.31 Million |
-16.95% |
| 2015-12-31 | ₩59.18 Billion ≈ $40.10 Million |
-3.75% |
| 2014-12-31 | ₩61.48 Billion ≈ $41.66 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Jin Yang Pharmaceutical Co. Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 137.3% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₩109.57 Billion | 68.54% |
| Other Components | ₩50.29 Billion | 31.46% |
| Total Equity | ₩159.86 Billion | 100.00% |
Jin Yang Pharmaceutical Co. Ltd Competitors by Market Cap
The table below lists competitors of Jin Yang Pharmaceutical Co. Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Ocean Group JSC
VN:OGC
|
$33.05 Million |
|
Union Corporation
KO:000910
|
$33.06 Million |
|
EP Manufacturing Bhd
KLSE:7773
|
$33.07 Million |
|
Medicamen Biotech Limited
NSE:MEDICAMEQ
|
$33.12 Million |
|
Korea Ind
KO:002140
|
$33.02 Million |
|
Chumpower Machinery Corp
TWO:4575
|
$33.02 Million |
|
iCRAFT Co. Ltd
KQ:052460
|
$33.02 Million |
|
Workhorse Group Inc
NASDAQ:WKHS
|
$33.01 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Jin Yang Pharmaceutical Co. Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 119,877,794,630 to 159,856,760,000, a change of 39,978,965,370 (33.3%).
- Net income of 22,286,848,620 contributed positively to equity growth.
- Dividend payments of 1,714,017,300 reduced retained earnings.
- New share issuances of 3,123,716,210 increased equity.
- Other factors increased equity by 16,282,417,840.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩22.29 Billion | +13.94% |
| Dividends Paid | ₩1.71 Billion | -1.07% |
| Share Issuances | ₩3.12 Billion | +1.95% |
| Other Changes | ₩16.28 Billion | +10.19% |
| Total Change | ₩- | 33.35% |
Book Value vs Market Value Analysis
This analysis compares Jin Yang Pharmaceutical Co. Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.30x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 0.90x to 0.30x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | ₩4396.94 | ₩3945.00 | x |
| 2017-12-31 | ₩3791.68 | ₩3945.00 | x |
| 2018-12-31 | ₩3761.85 | ₩3945.00 | x |
| 2019-12-31 | ₩3906.64 | ₩3945.00 | x |
| 2020-12-31 | ₩4143.24 | ₩3945.00 | x |
| 2021-12-31 | ₩5843.72 | ₩3945.00 | x |
| 2022-12-31 | ₩7199.14 | ₩3945.00 | x |
| 2023-12-31 | ₩8313.54 | ₩3945.00 | x |
| 2024-12-31 | ₩10490.95 | ₩3945.00 | x |
| 2025-12-31 | ₩12939.29 | ₩3945.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Jin Yang Pharmaceutical Co. Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 13.94%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 18.47%
- • Asset Turnover: 0.45x
- • Equity Multiplier: 1.68x
- Recent ROE (13.94%) is above the historical average (5.83%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | 6.53% | 8.87% | 0.59x | 1.25x | ₩-2.14 Billion |
| 2015 | -1.70% | -2.50% | 0.46x | 1.47x | ₩-6.92 Billion |
| 2016 | -18.51% | -25.18% | 0.47x | 1.56x | ₩-14.01 Billion |
| 2017 | -13.61% | -13.28% | 0.59x | 1.74x | ₩-10.01 Billion |
| 2018 | 2.22% | 1.99% | 0.67x | 1.67x | ₩-3.27 Billion |
| 2019 | 3.77% | 3.48% | 0.69x | 1.56x | ₩-2.72 Billion |
| 2020 | 7.94% | 7.53% | 0.72x | 1.47x | ₩-954.47 Million |
| 2021 | 14.60% | 15.18% | 0.64x | 1.51x | ₩3.01 Billion |
| 2022 | 15.87% | 16.14% | 0.67x | 1.48x | ₩4.55 Billion |
| 2023 | 14.13% | 13.45% | 0.78x | 1.34x | ₩3.70 Billion |
| 2024 | 24.77% | 26.20% | 0.50x | 1.90x | ₩17.71 Billion |
| 2025 | 13.94% | 18.47% | 0.45x | 1.68x | ₩6.30 Billion |
Industry Comparison
This section compares Jin Yang Pharmaceutical Co. Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $329,362,045,253
- Average return on equity (ROE) among peers: 3.99%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Jin Yang Pharmaceutical Co. Ltd (007370) | ₩159.98 Billion | 6.53% | 0.70x | $33.03 Million |
| Dongwha Pharm.Co.Ltd (000020) | $297.40 Billion | 3.39% | 0.25x | $97.49 Million |
| Yuhan Corp. (000100) | $519.03 Billion | 9.81% | 0.47x | $3.90 Billion |
| Yuhan Corp Preferred (000105) | $1.65 Trillion | 3.48% | 0.32x | $51.83 Million |
| Yuyu Pharma (000220) | $128.69 Billion | -1.72% | 0.50x | $43.48 Million |
| Yuyu Pharma Inc (000225) | $120.36 Billion | -5.97% | 0.65x | $14.47 Million |
| Yuyu Pharma Inc (000227) | $86.87 Billion | 4.63% | 0.56x | $42.09 Million |
| Ildong Holdings Co Ltd (000230) | $55.81 Billion | 8.24% | 2.38x | $53.57 Million |
| Samil Pharm (000520) | $54.41 Billion | 1.08% | 0.83x | $101.43 Million |
| Donga Socio Holdings (000640) | $266.72 Billion | 7.48% | 1.59x | $367.37 Million |
| Jw Pharmac (001060) | $112.60 Billion | 9.51% | 2.66x | $416.42 Million |
About Jin Yang Pharmaceutical Co. Ltd
Jin Yang Pharmaceutical Co., Ltd. engages in the pharmaceutical business in South Korea. The company offers crivix tablets, Eszol tablets, atolan tablets, prescription drugs, and over-the-counter drugs. It also offers antilipidemic, antiplatelet, gastrointestinal, and respiratory agents; antithrombotics; NSAIDs; menopause symptoms treatment; and stomatological products. The company also exports i… Read more